Aura names Natalie Holles CEO, and other biotech management moves

Natalie Holles has succeeded founder Elisabet de los Pinos as president, CEO and a director of  Aura Biosciences Inc. (NASDAQ:AURA). Holles served as CEO of Third Harmonic Bio Inc., which liquidated last year, and Audentes Therapeutics Inc., which was acquired by Astellas Inc. (Tokyo:4503) for $3 billion. She takes the reins as Aura’s Phase III CoMpass trial of belzupacap sarotalocan for early choroidal melanoma nears completion of enrollment. Top-line data are due in 2H27...